Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-10

Clinical Trial Update: Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old [Phase 3]

View source ↗

Summary

Phase 3 safety study of a herpes simplex vaccine in HSV seronegative and seropositive females aged 10-17 completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GlaxoSmithKline herpes simplex vaccine (unknown)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Simplex | Phase 3 | Status: COMPLETED | Results posted: 2017-04-10